Levetiracetam

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released January 20, 2000; last updated January 7, 2017; expires January 7, 2020

Historical note and terminology

Levetiracetam is a pyrrolidone derivative and not related to any of the antiepileptic drugs currently in use. It has been approved by the Food and Drug Administration in the United States, and also in the European Union and various other countries. Although levetiracetam is more expensive than traditional antiepileptic drugs, its cost is comparable to that of newer antiepileptic drugs.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.